Long-term efficacy of tamsulosin in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in real-life practice

UroToday International Journal

Volumn 2, Issue 1, 2009, Pages

  Yamanishi, Tomonori ^a   Tatssumiya, Katsuhisa ^a   Furuya, Nobutaka ^a   Masuda, Akinori ^a   Kamai, Takao ^a   Sakakibara, Ryuji ^a   Uchiyama, Tomoyuki ^a   Yoshida, Ken Ichiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alpha blocker; Benign prostatic hyperplasia; Lower urinary tract symptoms; Pharmacotherapy; Tamsulosin

Indexed keywords

EID: 61849123742     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: 10.3834/uij.1939.4810.2008.12.04     Document Type: Article

References (25)

1. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Use of an alpha1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group. J Urol. 1990 Oct;144(4):908-12
2. Yamanishi T, Yasuda K, Kamai T, Tsujii T, Sakakibara R, Uchiyama T, Yoshida K. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol. 2004 Jul;11(7):501-9
3. Wilt T, MacDonald R, Nelson D. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol. 2002 Jan;167(1):177-83.
4. Abrams P, Schulman CC, Vaage S and the European Tamsulosin Study Group. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction. Br J Urol. 1995 Sep;76(3):325-36.
5. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998 Jun;51(6):892-900
6. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol. 2000 Jun;163(6):1725-9
7. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther. 1997 Jul-Aug;19(4):730-42.
8. Schulman CC, Lock TM, Buzelin J-M, Boeminghaus F, Stephenson TP, Talja M; European Tamsulosin Study Group. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001 Oct;166(4):1358-63.
9. Narayan P, Evans CP, Moon T. Long-term safety of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003 Aug;170(2 Pt 1):498-502.
10. de la Rosette JJMCH, Kortman BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol. 2002 Apr;167(4):1734-9.
11. Kawabe K, Homma Y, Kubota K, Sozu T; Tamsulosin Long-term Study Group. How frequent are invasive therapies required in patients with receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study. Int J Urol. 2006 Feb;13(2):127-31.
12. Ichioka K, Ohara H, Terada N, Matsui Y, Yoshimura K, Terai A, Arai Y. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int J Urol. 2004 Oct;11(10):870-5.
13. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F; CombAT Study Group: The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008 Feb;179(2):616-21
14. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78.
15. Schwinn DA, Claus G Roehrborn. Alpha1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008 Mar;15(3):193-9.
16. Roehrborn CG, Abbou CC, Allona-Almagro A, Boccon-Gibod L, Ekman PE, Fourcroy J, et al. BPH: Clinical research criteria. In: Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, et al. (eds). Proceedings of the 4th International Consultation of Benign Prostatic Hyperplasia: Plymouth: Plymbridge Distributors Ltd. 1998; 437-91.
17. Yamanishi T, Takei K, Tobe T, Ueda T, Ito H, Yasuda K. Transurethral holmium: YAG laser prostatectomy using a side-firing fiber for bladder outlet obstruction due to benign prostatic enlargement: urodynamic evaluation of surgical outcome. Eur Urol. 2001 May;39(5):544-50.
18. Yamanishi T, Yasuda K, Sakakibara R, Hattori T, Tojo M. Effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy. BJU Int. 2000 Feb;85(3):249-53.
19. Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005; 5(2): 237-45.
20. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H, Tokai Urological Clinical Trial Group. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int. 2005 Sep;96(4):581-6.
21. Ikemoto I, Kiyota H, Ohishi Y, Abe K, Goto H, Kishimoto K, Miki K. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int J Urol. 2003 Nov;10(11):587-94.
22. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006 Apr;97(4):747-51.
23. Momose H, Hosokawa Y, Kishino T, Ono T, Oyama N. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs Today (Barc). 2007 Feb;43 Suppl A:1-10.
24. Takei R, Ikegaki I, Shibata K, Tsujimoto G, Asano T. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999;79(4):447-54.
25. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha-1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36(1):1-13.